Several other equities research analysts have also recently commented on the company. TheStreet cut Qiagen from a b- rating to a c+ rating in a report on Thursday, February 8th. Morgan Stanley increased their price target on Qiagen from $38.00 to $39.00 and gave the company an overweight rating in a report on Friday, February 2nd. BidaskClub cut Qiagen from a buy rating to a hold rating in a report on Thursday, March 15th. Zacks Investment Research raised Qiagen from a sell rating to a hold rating in a report on Tuesday, February 6th. Finally, Commerzbank reaffirmed a buy rating on shares of Qiagen in a report on Friday, January 19th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Qiagen presently has a consensus rating of Hold and a consensus target price of $35.55.
Shares of Qiagen stock opened at $35.46 on Wednesday. Qiagen has a 12 month low of $30.20 and a 12 month high of $36.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59.
Qiagen (NASDAQ:QGEN) last announced its earnings results on Wednesday, May 2nd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The business had revenue of $343.60 million during the quarter, compared to analysts’ expectations of $339.30 million. During the same quarter in the prior year, the firm earned $0.22 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. equities research analysts expect that Qiagen will post 1.34 EPS for the current fiscal year.
Qiagen declared that its Board of Directors has authorized a stock repurchase program on Wednesday, January 31st that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.
A number of institutional investors have recently modified their holdings of QGEN. American International Group Inc. purchased a new position in Qiagen in the fourth quarter worth approximately $154,000. M&T Bank Corp purchased a new position in Qiagen in the first quarter worth approximately $207,000. Lourd Capital LLC purchased a new position in Qiagen in the fourth quarter worth approximately $223,000. Clinton Group Inc. purchased a new position in Qiagen in the first quarter worth approximately $255,000. Finally, Forward Management LLC purchased a new position in Qiagen in the first quarter worth approximately $309,000. Institutional investors own 62.23% of the company’s stock.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.